Reviewing VistaGen Therapeutics Inc. (VTGN)’s and Moleculin Biotech Inc. (NASDAQ:MBRX)’s results

VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Moleculin Biotech Inc. (NASDAQ:MBRX) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VistaGen Therapeutics Inc. N/A 0.00 24.06M -0.93 0.00
Moleculin Biotech Inc. N/A 0.00 11.88M -0.51 0.00

In table 1 we can see VistaGen Therapeutics Inc. and Moleculin Biotech Inc.’s top-line revenue, earnings per share and valuation.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
VistaGen Therapeutics Inc. 0.00% -608.9% -267.7%
Moleculin Biotech Inc. 0.00% 0% 0%


3.6 and 3.6 are the respective Current Ratio and a Quick Ratio of VistaGen Therapeutics Inc. Its rival Moleculin Biotech Inc.’s Current and Quick Ratios are 2.1 and 2.1 respectively. VistaGen Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Moleculin Biotech Inc.

Insider and Institutional Ownership

VistaGen Therapeutics Inc. and Moleculin Biotech Inc. has shares held by institutional investors as follows: 18% and 8%. Insiders held roughly 0.1% of VistaGen Therapeutics Inc.’s shares. Insiders Comparatively, held 24.24% of Moleculin Biotech Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
VistaGen Therapeutics Inc. -16.18% -30.91% -33.33% -23.49% -3.39% -24%
Moleculin Biotech Inc. -5.71% -1.49% -1.49% -24.14% -30.16% 26.92%

For the past year VistaGen Therapeutics Inc. has -24% weaker performance while Moleculin Biotech Inc. has 26.92% stronger performance.


Moleculin Biotech Inc. beats on 5 of the 6 factors VistaGen Therapeutics Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. It also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by MoleculinÂ’s pre-clinical drug WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.